View our top seven events to look out for this week (6-10 February), plus our key company earnings schedule.
Will markets face further Brexit turmoil over Article 50?
Chief market analyst Michael Hewson looks at what the Trump administration might do next, the latest China trade data and next steps in the Article 50 debate.
Sky’s the limit for Twenty-First Century Fox
Monday: At the end of Q1, Twenty-First Century Fox posted a 22% increase in income, driven by higher subscriptions and advertising revenue. Monday’s Q2 update is likely to show a similar trend, but of most interest is whether the company believes its latest bid for Sky will succeed.
Can BP refine its profits?
Tuesday: The fall in oil prices over the last two years has placed an enormous strain on margins. At the end of Q3 BP’s profit almost halved, and while prices have rebounded, concerns still remain over its dividend. Will full-year results signal further capital expenditure cuts, or portray a more optimistic outlook?
Is the force still with Disney?
Tuesday: Walt Disney raised a few eyebrows in 2012 when it paid over $4bn for Lucasfilm, with some doubting it would recoup the money. It turned out to be a shrewd move after Star Wars: The Force Awakens helped Disney to a record quarterly profit. Will the recent release of Rogue One have a similar effect on Q1 earnings?
GlaxoSmithKline to reveal drug trial plans
Wednesday: When GlaxoSmithKline reported at the end of last year, the fall in the pound helped boost profit substantially, with over 90% of sales from outside the UK. Will this week’s full-year results be similarly positive, and more importantly will its pending pipeline of drug trials reap benefits?
Are Rio Tinto set to strike gold?
Wednesday: The rebound in iron ore and other metal prices has been a boon to the mining sector, with Rio Tinto's shares up nearly 100% in the past year. After last month’s disposal of Yancoal for £1.9bn there are high expectations for this week’s annual results, with a $3bn capital programme also expected to be launched.
Twitter Q4 results may finally show a profit
Thursday: Twitter's inability to effectively monetise its user base has long been a source of frustration, as it loses out to rivals like Instagram and Snapchat. However, advertising revenue has shown signs of improving, while takeover speculation is never far away. Its Q4 update will confirm whether its live-streaming ‘January transfer window’ deal with Sky helped to engage new users.
Selected UK & US company earnings schedule
|Monday 6 February||Results|
|easyJet (UK)||January sales & revenue|
|Twenty-First Century Fox (US)||Q2|
|Tyson Foods (US)||Q1|
|Tuesday 7 February||Results|
|Cardinal Health (US)||Q2|
|Emerson Electric (US)||Q1|
|General Motors (US)||Q4|
|Genworth Financial (US)||Q4|
|Gilead Sciences (US)||Q4|
|Intercontinental Exchange (US)||Q4|
|Michael Kors (US)||Q3|
|New Relic (US)||Q3|
|O'Reilly Automotive (US)||Q4|
|Pioneer Natural Resources (US)||Q4|
|Plains All American Pipeline (US)||Q4|
|S&P Global (US)||Q4|
|Vulcan Materials (US)||Q4|
|Walt Disney (US)||Q1|
|Yum China (US)||Q4|
|Wednesday 8 February||Results|
|Lions Gate Entertainment (US)||Q3|
|Rio Tinto (UK)||Full-year|
|Time Warner (US)||Q4|
|Tullow Oil (UK)||Full-year|
|Whole Foods Market (US)||Q1|
|Thursday 9 February||Results|
|Activision Blizzard (US)||Q4|
|Cliffs Natural Resources (US)||Q4|
|CVS Health (US)||Q4|
|Mohwak Industries (US)||Q4|
|Occidental Petroleum (US)||Q4|
|Pandora Media (US)||Q4|
|Patterson-UTI Energy (US)||Q4|
|Western Union (US)||Q4|
|Yum Brands (US)||Q4|
|Zayo Group (US)||Q2|
|Friday 10 February||No major results scheduled|
Company announcements are subject to change. All the events listed above were correct at the time of writing.
CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.